{"schema_version":"secwatch.filing_event.v1","accession":"0001145197-23-000047","form_type":"8-K","ticker":"PODD","cik":"0001145197","company_name":"INSULET CORP","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.064383+00:00","generated_at":"2026-06-14T05:38:26.173485+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Insulet extends Amgen supply agreement through 2028, adds IP license","bullets":["Amendment 21 extends term to December 31, 2028; parties to negotiate renewal by Jan 1, 2027.","Insulet and Amgen entered a Patent Assignment and License Agreement for IP rights.","New manufacturing site(s) added; Insulet responsible for equipment/labor to maintain quality.","Minimum purchase commitments revised but specific amounts redacted.","Payment terms amended; Safety Agreement terminated."],"urls":{"canonical":"https://secwatch.observer/filing/0001145197-23-000047","json":"https://secwatch.observer/filing/0001145197-23-000047.json","markdown":"https://secwatch.observer/filing/0001145197-23-000047.md","text":"https://secwatch.observer/filing/0001145197-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1145197/000114519723000047/0001145197-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1145197/000114519723000047/podd-20230601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:38:26.173485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf164af10f93fbe298d7c30278870a8836cde80c","claim":"INSULET CORP amended Amendment Number 21 with Amgen Inc. (effective 2023-06-01).","evidence_excerpt":"On June 1, 2023, Insulet Corporation (the “ Company ”) and Amgen Inc. (“ Amgen ”) entered into Amendment Number 21 (“ Amendment 21 ”) to the Supply Agreement, dated as of November 21, 2013, between the Company and Amgen, as amended by Amendments 1-20, pursuant to which Insulet manufactures and sells to Amgen customized devices (the “ Original Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1145197/000114519723000047/0001145197-23-000047-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Amgen Inc."},{"label":"Effective","value":"2023-06-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}